Bayesian random effects meta-analysis of trials with binary outcomes: Methods for the absolute risk difference and relative risk scales

Statistics in Medicine

Volumn 21, Issue 11, 2002, Pages 1601-1623

  Warn, D E ^a   Thompson, S G ^a   Spiegelhalter, D J ^a  

^a MRC BIOSTATISTICS UNIT   (United Kingdom)

Author keywords

Absolute risk difference; Bayesian methods; Binary data; Meta analysis; Relative risk

Indexed keywords

ANALGESIC AGENT; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ARTICLE; BAYES THEOREM; BINOMIAL DISTRIBUTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DATA ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; HUMAN; META ANALYSIS; METHODOLOGY; OUTCOMES RESEARCH; POSTOPERATIVE PAIN; RANDOMIZATION; RATING SCALE; RISK ASSESSMENT; SAMPLING; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BAYES THEOREM; CLINICAL TRIALS; HUMANS; IBUPROFEN; META-ANALYSIS; PAIN; RISK;

EID: 0037098198     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1189     Document Type: Article

References (51)

1. Bayesian approaches to random-effects meta-analysis: A comparative study
2. Exploring heterogeneity in randomized trials via meta-analysis
3. Systematic reviews of trials and other studies
4. Borrowing strength from external trials in a meta-analysis
5. Investigating underlying risk as a source of heterogeneity in meta-analysis
6. Meta-analysis: Formulating, evaluating, combining, and reporting
7. Effect measures for meta-analysis of trials with binary outcomes
8. Evidence-based medicine: An incomplete method for informing treatment choices
9. The number needed to treat: A clinically useful measure of treatment effect
10. Confidence intervals for the number needed to treat
11. Number needed to treat: Properties and problems
12. Single dose oral ibuprofen and diclofenac for post-operative pain (Cochrane Review)
13. Meta-analysis in clinical research
14. The relation between treatment benefit and underlying risk in meta-analysis
15. Interpreting evidence from multiple randomised and non-randomised studies
16. Investigating underlying risk as a source of heterogeneity in meta-analysis
17. Investigating underlying risk as a source of heterogeneity in meta-analysis
18. Comparing institutional performance using Markov chain Monte Carlo methods
19. A bivariate approach to meta-analysis
20. Meta-analysis for 2 × 2 tables: A Bayesian approach
21. Bayesian Data Analysis
22. The statistical basis of meta-analysis
23. A general parametric approach to meta-analysis of randomized clinical trials
24. Analysis of Binary Data
25. Meta-analysis in clinical trials
26. A language and program for complex Bayesian modelling
27. BUGS 0.5 Bayesian inference using Gibbs Sampling Manual
28. A single series from the Gibbs sampler provides a false sense of security
29. Evaluating the accuracy of sampling-based approaches to calculating posterior moments
30. How many iterations in the Gibbs sampler?
31. Meta-analysis regression
32. Meta-analysis in STATA
33. Explaining heterogeneity in meta-analysis: A comparison of methods
34. Comment on 'Hierarchical models for combining information and for meta-analyses'
35. Reference Bayesian methods for generalized linear mixed models
36. A prior for the variance in hierarchical models
37. Heterogeneity and statistical significance in meta-analysis: An empirical study of 125 meta-analyses
38. Why sources of heterogeneity in meta-analyses should be investigated
39. Summing up evidence: One answer is not always enough
40. A random effects regression model for meta-analysis
41. Cholesterol lowering and mortality: The importance of considering the initial level of risk
42. The population risk as an explanatory variable in research synthesis of clinical trials
43. Variation in baseline risk as an explanation of heterogeneity in meta-analysis
44. Importance of trends in the interpretation of an overall odds ratio in the meta-analysis of clinical trials
45. Who benefits most from medical interventions?
46. An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials
47. Incorporating variability in estimates of heterogeneity in the random effects model in meta-analysis
48. Size is everything-large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects
49. Uses of ecological analysis in epidemiological research
50. Quantitative methods in the review of epidemiological literature
51. Bayesian approaches to randomized trials